Compare the Prognostic Differences Between SBRT and Surgery for NSCLC Patients With Interlobular Fissure Invasion.

Main purpose:

Explore the survival differences between SBRT and surgery for NSCLC patients with interlobular pleural invasion.

Secondary purpose:

• Longitudinal exploration of the differences in heart and lung function changes before and after treatment between SBRT and surgery of NSCLC patients with interlobular pleural invasion
• Longitudinal exploration of dynamic changes in lung lobe volume before and after treatment in NSCLC patients with interlobular pleural invasion treated with SBRT and surgical intervention.

Inclusion criteria

• Voluntarily participate and sign an informed consent form in writing;
• Age 18 and above, regardless of gender;
• Diagnosed as primary lung cancer through imaging/pathology, meeting the indications for SBRT and surgical treatment;
• The clinical staging is cIB-IIIB stage (cT2-3N0M0), regardless of whether the staging is overestimated or underestimated as confirmed by pathology;
• Imaging diagnosis of NSCLC patients with tumor invasion of interlobular pleura;
• No serious abnormalities in the blood system, heart, lungs, liver, kidney function, or immune deficiency;
• There are no restrictions on surgical methods, and both VATS and open chest surgery are acceptable;
• Physical condition score ECOG level 0-2;
• Expected survival time>3 months.

Exclusion criteria

• Pathological confirmation of small cell lung cancer;
• Non solitary lung cancer, non primary lung cancer, with distant metastasis;
• Individuals with a history of severe lung or heart disease;
• Severe comorbidities, such as uncontrolled hypertension, heart failure, etc;
• Pregnant or lactating women;
• Previous history of malignant tumors;
• Refusal or inability to sign the informed consent form for participating in the trial.